expect result less import commentari effort restor
top-lin trajectori in-lin weight averag market growth rate without
provid formal guidanc telegraph view reason
outlook year one larg reflect street number remain market
perform pend greater evid turnaround
challeng comp one-tim factor signal sequenti revenu deceler
although guidanc explicitli provid manag expect lower
revenu growth sequenti due less accommod revenu comp revenu
tailwind continu includ tender asia pacif emea
capit sale benefit within set busi revenu comp
constant currenc bill day basi easiest year prior year period
part impact hurrican maria ultim provid tailwind
 busi revenu estim prior estim
adjust deeper fx headwind approxim consensu
estim constant currenc bill day adjust basi forecast
revenu growth sequenti deceler growth calcul
assum bill day benefit quarter revenu estim
assum fx headwind vs previous reflect currenc move sinc
report result revenu estim also includ inorgan contribut
sell day tailwind partial addit day ep estim four
cent consensu estim part due top-lin fx adjust
account per share
maintain market perform reduc price
reduc price target previous account
downward trend estim past month multipl compress across
sector target base earn multipl
ebitda amount approxim two turn discount peer group
view appropri given lower top line growth profil could becom
construct pend visibl revenu acceler driver improv
execut remain sidelin market perform rate
pleas see page report import disclosur
market perform rate stem zbh outsiz exposur reconstruct joint
market make compani heavili reliant hip knee implant year
weak recon market cap sale growth biomet merger continu
roll-out persona knee system better-posit captur market share
strengthen recon busi howev recent suppli issu delay zbh return
market growth rate remedi suppli constraint demonstr sustain
improv recon well compani non-recon area key
remedi manufactur issu
led recent fda
elimin exist suppli constraint
resolut suppli constraint line
manag guidanc
faster-than-expect resolut
continu success integr
continu stabil global
merger acquisit synergi
anticip
deterior global recon market
market share loss knee hip
design sell reconstruct spinal trauma devic compani also
biolog sport medicin dental bone heal microfix relat surgic devic
product portfolio manag oper three geograph segment
america consist unit state includ north central
south american market europ consist europ includ middl east
africa market asia pacif compris japan australia select market
zimmer merg biomet june greatli expand orthoped scale
solid could improv convict potenti upsid expect
manag latest sale growth guidanc report basi
account expect currenc benefit low-end
rang impli organ cc growth though low-end comment obvious
appli within revenu guidanc bone cement issu expect
quarterli headwind start manag continu believ
suppli constraint barrier hit guidanc target
believ part de-risk number end year anticip
adjust effect tax rate slightli low end
impli tax rate ep guidanc impli
ep rang full-year free cash flow guidanc stand
capital-expenditure assumpt cash flow oper project
also reiter call non-gaap oper margin target
full year
believ consensu revenu estim repres appropri conserv
outlook junctur turnaround
current forecast revenu vs consensu estim
organ revenu growth flat oper margin expans ep vs consensu
estim believ reason start point enter year
earn call manag provid ampl level detail underli
oper assumpt although discuss spare formal guidanc
noteworthi detail manag expect return busi
weight averag market growth rate recent investor confer
manag reiter target also growth like come
level manag emphas call foremost prioriti today
acceler revenu growth requir increas level invest
next sever quarter invest appear intend impact alreadi
seek achiev previous commun target grow in-lin
weight averag market growth rate although zbh exist pipelin capabl
achiev in-lin market growth manag state market growth
requir aggress portfolio manag diversifi busi migrat
transit beyond focu product suppli upcom quarter instead hone
cost reduct manufactur improv drive margin expans
accomplish includ improv suppli new product introduct
togeth reinvigor sale forc traction enhanc surgeon relationship
recent launch persona partial knee persona tm tibia produc favor
result tm tibia exceed case limit launch upcom
launch persona revis system rosa robot progress in-lin
expect rosa slightli ahead although lack suppli expect barrier
target manag note still take time fulli restor
salesforc confid inventori allow go fulli offens
expect full product portfolio includ key pipelin product like rosa
second half point salesforc offens
current spot rate fx like creat headwind report revenu
vs manag expect headwind heavili skew toward
one notabl headwind address earn call disrupt relat
pend termin distribut agreement zbh bone cement supplier
dynam expect impact per quarter begin
headwind expect persist next sever quarter
fulli transit custom intern produc bone cement although highlight
later note believ expect financi impact event alreadi
account stock
although signific om expans unlik top-lin stabil re-rout
although manag provid explicit margin guidanc rang
repres midpoint slightli forecast
estim gross margin oper margin gross margin estim
repres yoy declin though slight improv yoy declin
much higher spend product today continu capit
inventori therefor elev cost implement dual-sourc
strategi instal effici manufactur qualiti control process
fulli reflect inventori fulli turn anticip
 forecast sale repres increas previou year
continu invest new product robot also expect bp yoy
increas sg manag continu invest build
special sale forc potenti incent recon rep remain loyal
hous although factor equat yoy margin contract believ om
hit floor improv sequenti hit
full year guidanc rang remain optimist zbh multi-year margin expans
potenti stem initi around manufactur effici soften suppli
headwind sku ration top-lin leverag believ guidanc like
reiter manag prior messag indic flat om perform
although believ investor continu priorit revenu growth much
continu execut front could re-rout investor focu untap share
headwind tailwind busi
knee knee face weak comp constant currenc growth
forecast deliv ww knee sale growth constant currenc
constant bill day would mark sequenti deceler constant
currenc growth constant bill day momentum recent
launch persona partial knee tm tibia system continu aid franchis
receiv posit feedback surgeon custom review
fda web site suggest persona revis system clear right around
time call believ approv flown radar investor
offer sourc upsid busi unit collect product
like modest contribut given launch time although believ
recent product introduct upcom posit sign compani abil
drive innov cycl despit broader oper distract
hip except strong quarter hip deliv constant bill day
growth manag mention call although perform result
effort made suppli chain recoveri traction sale team
product portfolio easi comp hip face previou year
constant bill day key driver mark expect
said still make progress hip like post anoth posit quarter
franchis even deceler estim growth
constant bill day comp asia like repres area
 busi face strong constant currenc bill day growth comp
mark second strongest quarter franchis constant
currenc bill day growth estim quarter step yoy basi
also sequenti previou quarter deliv growth
call comment compani suppli issu hinder
busi like hip knee issu still work remedi
also mention product launch solid sale gel-on subchondroplasti
quattro link plate system provid tailwind segment
suppli begin improv
spine/cmf/thorac although spine craniomaxillofaci cmf growth past
year burden soft spine market revenu dis-synergi relat
integr ldr look stabil franchis make progress
toward turnaround forecast constant currenc growth
adjust bill day weak constant currenc bill day comp
decis make chang within senior leadership spine allow channel
strategi time develop appear pay strung togeth consecut
quarter posit growth put issu behind
also allow focu shift toward excit develop
product pipelin like impend fda approv rosa robot spine
applic help bring promis growth profil perspect
investor recent investor confer manag project rosa spine approv
despit govern shutdown limit launch soon thereaft potenti
dental given histor weak franchis result restructur
competit market dynam dental one zbh weaker busi sever
quarter headwind like continu impact dental estim growth
constant currenc growth adjust bill day would impli
continu market share eros near term restructur sale forc key
market yet yield meaning sale benefit manag previous
heraeu dynam disrupt
alreadi understood factor
rosa commentari expect
hot topic
state busi begin stabil focus return
franchis posit growth
heraeu medic decis begin direct sale palaco bone cement end
exclus distributor relationship zimmer enjoy year despit consensu view
bone cement commod check surgeon suggest switch away
palaco may limit howev think zbh guidanc suitabl account
possibl heraeu medic announc decis begin direct sale palaco cement
 januari impact decis first felt signific
way weve contact sever orthoped surgeon current user
palaco cement includ also loyal larg joint system judg
whether theyll consid switch biomet cement stryker market cement
global though palaco europ narrowli
trail cement call simplex orthoped surgeon weve spoken
express willing chang cement palaco refobacin howev none
surgeon claim deep knowledg institut procur palaco
cement us suggest hospit may remain loyal palaco default long
keep product stock term what need drive switch away
palaco surgeon cite altern cement track record
acknowledg past success market palaco cement work
surgeon use product like achiev good result nonetheless
clinic data weve review show similar perform characterist
refobacin palaco help support switch decis away
palaco bone cement high-margin product that import reconstruct joint
manufactur estim zbh annual sale bone cement accessori total
north substanti amount howev guid palaco
disrupt impact per quarter begin continu
next sever quarter compani even outlin hit high end
rang nearest quarter first attempt transit palaco custom
intern produc bone cement therefor think guidanc repres
sale headwind fairli comprehens busi whose sale total
slightli annual reason believ compani recent guidanc
fulli account palaco setback leav littl increment downsid risk
call said two largest commerci project await regulatori
approv persona revis system rosa robot initi knee review
fda web site suggest persona revis system clear right
around time call regard rosa indic knee applic
progress line expect ahead schedul compani still
await regulatori approv knee well spine manag said
whether launch knee applic meaning alter
roll-out plan sinc robot make major revenu contribut earli stage
introduct also stress spine applic initi run
alreadi commerci rosa brain system knee separ piec
capit there futur opportun combin three applic singl unit
would like enabl user perform robot case per unit due multi-procedur
util system manag referenc australian surgeon perform five
rosa knee case singl day speak potenti effici benefit system
studi rosa total knee compani also emphas robot knee
spine signific develop product-advanc standpoint
globu mazor weve wit investor respond favor robot
launch even materi revenu contribut think persona rosa
much import zbh share price stage bone cement especi sinc
manag opinion adequ frame palaco issu comment
figur larg cap medic suppli devic trade comp
compani report thomson eikon cowen compani
compani report cowen compani
mm except oper biomet oper cowen
compani report cowen compani
mm except ex-fx ex-fx ex-fx ex-fx ex-fx ex-fx ex-fx ex-fx ex-fx spine ex-fx ex-fx ex-fx ex-fx revenu less cowen
valuat methodolog primarili base current year forward year ev/sal
ev/ebitda multipl well current year forward price-to-earnings multipl total return/p
ratio market cap/fre cash flow metric dividend yield comp
orthoped industri risk continu util pressur account
organ play bigger role health care deliveri competit dynam global
potenti regulatori delay reject failur devic clinic trial econom
sensit price pressur and/or weaken consum demand develop market
econom and/or polit uncertainti emerg market intellectu properti
deeper util pressur recon busi us europ worsen
competit dynam global potenti regulatori delay reject failur
devic clinic trial econom sensit price pressur and/or weaken
demand develop market econom and/or polit uncertainti emerg
market fluctuat foreign exchang rate
